All In Biotech

Drug Trial Radar · NCT00531817

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

A Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Tocilizumab (TCZ) Versus Placebo in Combination With Disease Modifying Antirheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

Last checked: Nov 20, 2026Latest source record: Aug 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 619 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

619

Actual

Start

Oct 2007

Primary completion

Jun 2009

Study completion Mar 2011

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 2-arm study assessed the safety and efficacy of tocilizumab versus placebo, both in combination with disease modifying antirheumatic drugs (DMARDs), in regard to reduction in signs and symptoms, in patients with moderate to severe active rheumatoid arthritis with an inadequate response to DMARDs. Patients were randomized in a ratio of 2:1 to receive either tocilizumab 8 mg/kg intravenously (IV) or placebo IV every 4 weeks. All patients also received stable antirheumatic therapy, including permitted DMARDs. The anticipated time on study treatment was 3-12 months and the target sample size was 500+ individuals.

Conditions

  • Rheumatoid Arthritis

Interventions

  • TocilizumabDrug

    Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.

  • PlaceboDrug

    Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.

  • Permitted DMARDsDrug

    As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With an Improvement of at Least 50% in American College of Rheumatology (ACR) Score (ACR50) From Baseline at Week 24Time frame: Baseline to Week 24

Locations

157 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Lake Havasu City, Arizona

  • Site not named

    Paradise Valley, Arizona

  • Site not named

    Peoria, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Beverly Hills, California

  • Site not named

    Escondido, California

  • Site not named

    La Jolla, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Pasadena, California

  • Site not named

    Santa Maria, California

  • Site not named

    Santa Monica, California

  • Site not named

    Upland, California

  • Site not named

    Van Nuys, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Whittier, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Trumbull, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Dunedin, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Lake Mary, Florida

  • Site not named

    Melbourne, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orange Park, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Palm Harbor, Florida

  • Site not named

    Plantation, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Tamarac, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Blue Ridge, Georgia

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.